Mostrando 2 resultados de: 2
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
ArticleAbstract: Background: Effective treatments for COVID-19 are urgently needed, but conducting randomized trialsPalabras claves:Autores:Anand S.S., Avezum A.J., Bangdiwala S.I., Belley-Cote E.P., Beresh H., Berwanger O., Bosch J.J., Chan N., Choudhri S., Dans A.L., DIaz R., Eikelboom J.W., Farkouh M.E., Felix Camilo, Harper W.L., Hassany M., Jolly S.S., Kazmi K., Kontsevaya A., Lewis G., Loeb M., Lopes R.D., Nkeshimana M., Orlandini A., Pais P., PATRICIO LOPEZ -JARAMILLO, Rangarajan S., Sharma S.K., Tarhuni W.M., Wasserman S., Whitlock R.P., Xavier D., Xu L., Yusuf S., Yusufali A.M.Fuentes:googlescopusThe cost implications of a polypill for primary prevention in the TIPS-3 trial
ArticleAbstract: Aims The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesPalabras claves:Cardiovascular disease, cost analysis, Polypill, Primary PreventionAutores:Dans A.L., Gamra H., Gao P., Joseph P.G., Lamy A., Pais P., PATRICIO LOPEZ -JARAMILLO, Santoso A., Talukder S.H., Tong W., Walli-Attaei M., Xavier D., Yusuf S.Fuentes:googlescopus